{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:31:50Z","timestamp":1794609110518,"version":"4.9.1"},"reference-count":97,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","award":["971557"],"award-info":[{"award-number":["971557"]}],"id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["16\/107\/05"],"award-info":[{"award-number":["16\/107\/05"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2022,1,31]]},"DOI":"10.1080\/21645515.2021.1895644","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T05:12:16Z","timestamp":1620796336000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":30,"title":["Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines"],"prefix":"10.1080","volume":"18","author":[{"given":"Gerardo","family":"Montalvo Zurbia-Flores","sequence":"first","affiliation":[{"name":"University of Oxford. The Henry Wellcome Building for Molecular Physiology","place":["Oxford, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine S","family":"Rollier","sequence":"additional","affiliation":[{"name":"University of Oxford and the NIHR Oxford Biomedical Research Centre","place":["Oxford, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Reyes-Sandoval","sequence":"additional","affiliation":[{"name":"University of Oxford. The Henry Wellcome Building for Molecular Physiology","place":["Oxford, UK"]},{"name":"Instituto Polit\u00e9cnico Nacional, IPN. Av. Luis Enrique Erro S\/n. Unidad Adolfo L\u00f3pez Mateos. CP","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2018.05.012"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(01)00016-0"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.8.960"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1209.05-0979"},{"key":"e_1_3_4_6_1","unstructured":"Yellow Fever 2019 case definition. Atlanta (USA): Centers of Disease Control and Prevention (CDC) \u00a02019 [accessed 2020 Oct 13]. https:\/\/wwwn.cdc.gov\/nndss\/conditions\/yellow-fever\/case-definition\/2019\/:NationalNotifiableDiseasesSurveillanceSystem(NNDSS)."},{"key":"e_1_3_4_7_1","article-title":"The effect of prolonged cultivation in vitro upon the pathogenicity of Yellow fever virus","volume":"65","author":"Theiler MSH","year":"1937","unstructured":"Theiler MSH. The effect of prolonged cultivation in vitro upon the pathogenicity of Yellow fever virus. J Exp Med. 1937;65:767\u201086.","journal-title":"J Exp Med"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408360490497474"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1606997"},{"key":"e_1_3_4_10_1","first-page":"7","article-title":"Disease resurgence, production capability issues and safety concerns in the context of an aging population: is there a need for a new yellow fever vaccine?","author":"Tomashek KM","year":"2019","unstructured":"Tomashek KM, Challberg M, Nayak SU, Schiltz HF. Disease resurgence, production capability issues and safety concerns in the context of an aging population: is there a need for a new yellow fever vaccine? Vaccines (Basel). 2019;7.","journal-title":"Vaccines (Basel)"},{"key":"e_1_3_4_11_1","unstructured":"A global strategy to eliminate Yellow fever epidemics 2017\u20132026. Geneva (Switzerland): World Health Organization 2018."},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-017-0566-9"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30116-7"},{"key":"e_1_3_4_14_1","unstructured":"Yellow fever: a current threat. Emergencies preparedness response. World Health Organization. [accessed 2020 Apr 3]. https:\/\/www.who.int\/csr\/disease\/yellowfev\/impact1\/en\/."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)07185-9"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2010.01.001"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2016.1180250"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.01079"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-019-1277-7"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2014.08.030"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31330-7"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.05.018"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20042565"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2018.03.009"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.03.032"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2015.1083430"},{"key":"e_1_3_4_27_1","unstructured":"Contraindications administering yellow fever vaccine. Atlanta (USA): Center of Disease Control. [accessed 2020 May 19]. https:\/\/www.cdc.gov\/travel-training\/local\/HistoryEpidemiologyandVaccination\/contraindications-administering-yellow-fever-vaccine.pdf."},{"key":"e_1_3_4_28_1","first-page":"26","article-title":"Yellow fever vaccination for immunocompromised travellers: unjustified vaccination hesitancy?","author":"De Jong W","year":"2019","unstructured":"De Jong W, De Man RA, Dalm V, Reusken C, Goeijenbier M, Van Gorp ECM. Yellow fever vaccination for immunocompromised travellers: unjustified vaccination hesitancy? J Travel Med. 2019;26.","journal-title":"J Travel Med"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.26633\/RPSP.2018.75"},{"key":"e_1_3_4_30_1","first-page":"4","article-title":"Yellow fever vaccine","author":"Monath TP","year":"2005","unstructured":"Monath TP. Yellow fever vaccine. Expert Rev Vaccines. 2005;4.","journal-title":"Expert Rev Vaccines"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40475-019-00194-x"},{"key":"e_1_3_4_32_1","unstructured":"United Nations. Fertility Data. World population prospects 2019. Depeartment of Economic and Social Affairs. Population Dynamics 2020[accessed 2020 Apr 3]. https:\/\/population.un.org\/wpp\/Download\/Standard\/Fertility\/."},{"key":"e_1_3_4_33_1","unstructured":"Q&A: fractional doses of the yellow fever vaccine. World Health Organization 2017 [accessed 2020 Apr 3]. https:\/\/www.who.int\/emergencies\/yellow-fever\/mediacentre\/qa-fractional-dosing\/en\/."},{"key":"e_1_3_4_34_1","unstructured":"Yellow fever. International travel and health. World Health Organization. [accessed 2021 Jan 4] https:\/\/www.who.int\/ith\/vaccines\/yf\/en\/#:~:text=The%20YF%20vaccine%20is%20contraindicated transmission%20may%20be%20very%20high."},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2012.06.003"},{"key":"e_1_3_4_36_1","unstructured":"World Health Organization. Cancer today. International Agency for Research on Cancer 2020 [accessed 2020 Apr 3]. https:\/\/gco.iarc.fr\/today\/online-analysis-map?v=2018&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17items=10&group_cancer=1&include_nmsc=1&include_nmsc_other=1&projection=globe&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=0&rotate=%255B10%252C0%255D."},{"key":"e_1_3_4_37_1","unstructured":"United Nations. AIDSinfo. UNAIDS 2020 [accessed 2020 Apr 3]. http:\/\/aidsinfo.unaids.org\/."},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001963"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.04.016"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.05.026"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.03.023"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70245-9"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.09.009"},{"key":"e_1_3_4_44_1","unstructured":"Our Wolrd in Data. Population by age bracket with UN projections World 1950 to 2020. Oxford Martin School University of Oxford 2020 [accessed 2020 Apr 3]. https:\/\/ourworldindata.org\/population-aged-65-outnumber-children."},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31838-4"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30195-7"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/1753-6561-5-S8-P52"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-018-9275-z"},{"key":"e_1_3_4_49_1","unstructured":"Organization WH Types of seasonal influenza vaccine. World Health Organization. [accessed 2021 Jan 6]. https:\/\/www.euro.who.int\/en\/health-topics\/communicable-diseases\/influenza\/vaccination\/types-of-seasonal-influenza-vaccine."},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.01.040"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.07.001"},{"key":"e_1_3_4_52_1","unstructured":"Temporary total depletion of US licensed yellow fever vaccine addressed by availability of stamaril vaccine at selected clinics. Centers for Disease Control and Prevention 2020 [accessed 2020 Nov 6]. https:\/\/wwwnc.cdc.gov\/travel\/news-announcements\/yellow-fever-vaccine-access."},{"key":"e_1_3_4_53_1","unstructured":"Yellow Fever Vaccine Information. Sanofi U.S. 2020[accessed 2020 Nov 6]. https:\/\/www.sanofi.us\/en\/products-and-resources\/vaccines\/yellow-fever-vaccine-information#:~:text=Sanofi%20Pasteur\u2019s%20new%20U.S.%20YF YF%2DVAX%20in%20December%202020."},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30494-2"},{"key":"e_1_3_4_55_1","unstructured":"Yellow fever global vaccine stockpile in emergencies. World Health Organization 2016 [accessed 2020 Apr 3]. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/yellow-fever-global-vaccine-stockpile-in-emergencies:."},{"key":"e_1_3_4_56_1","first-page":"379","article-title":"Fever vaccination \u2014 advancing the evidence base","author":"Vannice K","year":"2018","unstructured":"Vannice K, Wilder-Smith A, Fractional-Dose Yellow HJ. Fever vaccination \u2014 advancing the evidence base. N Engl J Med. 2018;379.","journal-title":"N Engl J Med"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30152-1"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01211"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1529"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/17441692.2018.1512144"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.13-0264"},{"key":"e_1_3_4_62_1","first-page":"26","article-title":"Fractional-dose yellow fever vaccination: an expert review","author":"Roukens AHE","year":"2019","unstructured":"Roukens AHE, Visser LG. Fractional-dose yellow fever vaccination: an expert review. J Travel Med. 2019;26.","journal-title":"J Travel Med"},{"key":"e_1_3_4_63_1","first-page":"24","article-title":"Importation of yellow fever into China: assessing travel patterns","author":"Wilder-Smith A","year":"2017","unstructured":"Wilder-Smith A, Leong WY. Importation of yellow fever into China: assessing travel patterns. J Travel Med. 2017;24.","journal-title":"J Travel Med"},{"key":"e_1_3_4_64_1","unstructured":"World Tourism Organization World Bank. Yearbook of tourism statistics. International arrivals. World Tourism Organization. [accessed 2020 Apr 3]. https:\/\/data.worldbank.org\/indicator\/st.int.arvl."},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.08347"},{"key":"e_1_3_4_66_1","unstructured":"WHO report on global surveillance of epidemic-prone infectious diseases - Yellow fever. Emergencies preparedness response. World health Organization. https:\/\/www.who.int\/csr\/resources\/publications\/yellowfev\/CSR_ISR_2000_1\/en\/index1.html."},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2019.00148"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.03.077"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qco.0000178823.28585.ad"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.034"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009303"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.10.015"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2014.07.050"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.000026"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2016.1175943"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003693"},{"key":"e_1_3_4_77_1","unstructured":"Safety and immunogenicity study of 2019-nCoV vaccine (mRNA-1273) for prophylaxis of SARS-CoV-2 infection (COVID-19). ClinicalTrials.gov NIH U.S. National Library fo Medicine 2020 [accessed 2020 Oct 13]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04283461."},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.06.017"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr2009737"},{"key":"e_1_3_4_80_1","first-page":"21","article-title":"RNA Viruses as RNA Vaccines","author":"Self-Amplifying LK","year":"2020","unstructured":"Self-Amplifying LK. RNA Viruses as RNA Vaccines. Int J Mol Sci. 2020;21.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01756"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2017.42"},{"key":"e_1_3_4_83_1","unstructured":"A phase I trial to evaluate the safety reactogenicity and immunogenicity of MVA-BN yellow fever vaccine with and without montanide ISA-720 adjuvant in 18-45 year old healthy volunteers (NCT02743455). ClinicalTrials.gov NIH U.S. National Library fo Medicine 2016 [accessed 2020 Apr 3]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02743455."},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024505"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2011.03.006"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(95)00032-V"},{"key":"e_1_3_4_87_1","first-page":"8","article-title":"Being pregnant during the Kivu Ebola virus outbreak in DR Congo: the rVSV-ZEBOV vaccine and its accessibility by mothers and infants during humanitarian crises and in conflict areas","author":"Schwartz DA","year":"2020","unstructured":"Schwartz DA. Being pregnant during the Kivu Ebola virus outbreak in DR Congo: the rVSV-ZEBOV vaccine and its accessibility by mothers and infants during humanitarian crises and in conflict areas. Vaccines (Basel). 2020;8.","journal-title":"Vaccines (Basel)"},{"key":"e_1_3_4_88_1","unstructured":"Effectiveness and safety of a heterologous two-dose Ebola vaccine in the DRC. ClinicalTrials.gov NIH U.S. National Library fo Medicine 2019 [accessed 2020 Oct 14]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04152486?term=Ad26.ZEBOV%2FMVA-BN-Filo&cond=Ebola&cntry=CD&draw=2&rank=2."},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0188-3"},{"key":"e_1_3_4_90_1","unstructured":"A study of a candidate COVID-19 vaccine (COV001). ClinicalTrials.gov NIH U.S. National Library fo Medicine 2020 [accessed 2020 May 18]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04324606."},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31604-4"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04859-5"},{"key":"e_1_3_4_93_1","unstructured":"Safety and immunogenicity of a candidate ZIKV vaccine (ZIKA001). ClinicalTrials.gov NIH U.S. National Library fo Medicine 2019 [accessed 2020 Apr 3]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04015648."},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040385"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29594"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"e_1_3_4_97_1","unstructured":"Immunization Schedules - Africa. University of Cape Town. [accessed 2021 Jan 17]. http:\/\/www.vacfa.uct.ac.za\/immunization-schedules-africa."},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30346-2"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2021.1895644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T19:09:38Z","timestamp":1744052978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2021.1895644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,31]]}},"alternative-id":["10.1080\/21645515.2021.1895644"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2021.1895644","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1895644"}}